Jasper Therapeutics Inc (JSPR)
Jasper Therapeutics Inc. is a clinical-stage biotechnology company listed on NASDAQ under the ticker JSPR. The company is developing therapies for mast cell-related conditions and diseases tied to hematopoietic stem cells. Its lead candidate, briquilimab, is a monoclonal antibody intended to interfere with CD117 signaling by preventing stem cell factor from binding to the receptor. Jasper is also working on treatment approaches for chronic spontaneous urticaria, chronic inducible urticaria, asthma, and conditioning use in stem cell transplantation for disorders such as sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. The company was founded in 2018 and is based in Redwood City, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-JSPR
|
$0.72
|
-12.8% Downside
|
Fair
|
$9.17 1,004.4% Upside
|
—
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 7, 2026
|
-0.4x
|
6.8x
|
—
|
22.792 M
|
9.85 M
|
3.2%
|
84.2%
|
-30.6
|
—
|
123.6%
|
